80 to 84-year-olds invited for vaccination sooner Starting tomorrow, the first people in the age group from 80-84 years in the Netherlands will receive an invitation from RIVM for a COVID-19 vaccination.
One person died shortly after COVID-19 vaccination The Pharmacovigilance Centre Lareb announced today that the centre had received a report of death shortly after receiving the Pfizer/BioNTech COVID-19 vaccination in the Netherlands.
Nationwide assessment of SARS-CoV-2 laboratories: very high quality The vast majority of the laboratories analysing COVID-19 tests are performing at the very highest standard of quality.
Joint Action CHRODIS PLUS: RIVM’s contribution to strengthening Health Promotion Within the Joint Action for the prevention and treatment of chronic diseases CHRODIS PLUS, RIVM has developed a set of recommendations for intersectoral cooperation to strengthen health promotion a
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
New data on antimicrobial resistance in Europe New data on antimicrobial resistance (AMR) in European countries is now available in the sixth annual report of the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) netw
International collaboration essential theme State of Zoonoses 2019 Each year, at the request of the Netherlands Food and Consumer Product Safety Authority, RIVM prepares an overview of the most important zoonoses and indicates their prevalence in the Netherlands.
Climate and Energy Outlook 2020: uncertain whether the Netherlands will achieve targets for the reduction of greenhouse gas emissions The Dutch cabinet’s goal is to reduce greenhouse gas emissions by 49% in 2030, compared to the levels in 1990.